{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:57:14Z","timestamp":1792900634442,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with precursor B-cell acute lymphoblastic leukemia (pB-ALL) who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT), have relapsed more than once, or are resistant upfront have a dismal prognosis. CD19-targeted chimeric antigen receptor (CAR) T cells have evolved as potent immune therapies. Tisagenlecleucel (Tisa-cel) is a commercially available autologous CD19-directed CAR T-cell product. We performed a retrospective study inviting all CAR T-cell centers in Germany to participate. Eighty-one patients with pB-ALL were included. Twenty-eight days after CAR T-cell infusion, 71 patients (87.7%) were in complete response, and 8 (9.9%) were in nonremission. At 2 years, the probabilities of event-free survival (pEFS), relapse-free survival (pRFS), and overall survival (pOS) were 45.3%, 51.7%, and 53.2%, respectively. pEFS was not different in patients without (n\u00a0= 16, 55.0%) vs with prior allo-HSCT (n\u00a0= 65, 43.4%). In patients treated after allo-HSCT, the time to relapse after allo-HSCT was a strong predictor of outcome. Patients relapsing within 6\u00a0months of allo-HSCT had a disappointing pEFS of 18.4% (pOS\u00a0= 16.0%); the pEFS for those relapsing later was 55.5% (pOS\u00a0= 74.8%). Our study provides real-world experience in pediatric, adolescent, and young adult patients with ALL treated with Tisa-cel, where most patients were treated after having relapsed after allo-HSCT. A total of 45.3% were rescued with a single dose of Tisa-cel. Our novel finding that patients with ALL after allo-HSCT had by far a better pEFS if relapse occurred beyond 6\u00a0months might be helpful in clinical decision-making and motivates studies to uncover the reasons.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008981","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:17:23Z","timestamp":1673029043000},"page":"2436-2448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":61,"title":["CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"first","affiliation":[{"name":"1Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-5285","authenticated-orcid":false,"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[{"name":"2Pediatric Hematology and Oncology, Muenster University Children's Hospital, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-8037","authenticated-orcid":false,"given":"Martin","family":"Hutter","sequence":"additional","affiliation":[{"name":"1Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ayuketang","family":"Ayuk","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation, Hamburg-Eppendorf University Medical Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine II, Schleswig-Holstein University Hospital, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7280","authenticated-orcid":false,"given":"Veit L.","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"5Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-2675","authenticated-orcid":false,"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[{"name":"6Goethe University Institute for Transfusion Medicine and lmmunohematology, Translational Development of Cellular Therapies, and German Red Cross Blood Service Baden-W\u00fcrttemberg\u2013Hesse, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"8Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[{"name":"9Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-1735","authenticated-orcid":false,"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Bakhtiar","sequence":"additional","affiliation":[{"name":"1Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-5412","authenticated-orcid":false,"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[{"name":"11Department of Pediatric Oncology and Hematology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0628","authenticated-orcid":false,"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[{"name":"12Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical lmmunology, Medical Faculty, Heinrich-Heine University, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen, Friedrich Alexander University of Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-6632","authenticated-orcid":false,"given":"Ingo","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"14Division of Pediatric, Stem Cell Transplantation and Immunology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Oncology and Tumorimmunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rettinger","sequence":"additional","affiliation":[{"name":"1Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sauer","sequence":"additional","affiliation":[{"name":"16Pediatric Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Gerhardt","family":"Schlegel","sequence":"additional","affiliation":[{"name":"17Department of Pediatric Hematology, Oncology, Stem Cell Transplantation, Wuerzburg University Children\u2019s Hospital, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Soerensen","sequence":"additional","affiliation":[{"name":"1Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[{"name":"11Department of Pediatric Oncology and Hematology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-130X","authenticated-orcid":false,"given":"Brigitte","family":"Strahm","sequence":"additional","affiliation":[{"name":"18Faculty of Medicine, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hauer","sequence":"additional","affiliation":[{"name":"19Department of Pediatrics, Pediatric Hematology and Oncology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany"},{"name":"20Department of Pediatrics, Children's Cancer Research Center, Kinderklinik M\u00fcnchen Schwabing, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-9681","authenticated-orcid":false,"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[{"name":"21Department Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr. von Hauner Children\u2019s Hospital, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-2697","authenticated-orcid":false,"given":"Andrea","family":"Jarisch","sequence":"additional","affiliation":[{"name":"1Division for Stem Cell Transplantation, Immunology and Intensive Care, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"3","key":"2023061218532895500_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A\u00a050-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"issue":"15","key":"2023061218532895500_bib2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023061218532895500_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","article-title":"Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM study group","volume":"47","author":"von Stackelberg","year":"2011","journal-title":"Eur J Cancer"},{"issue":"11","key":"2023061218532895500_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023061218532895500_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: A multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023061218532895500_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bjh.15511","article-title":"Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial","volume":"183","author":"Kuhlen","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"2023061218532895500_bib7","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2023061218532895500_bib8","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2023061218532895500_bib9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023061218532895500_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2023061218532895500_bib11","unstructured":"Bundesministerium f\u00fcr Gesundheit\n          . Ma\u00dfnahmen zur Qualit\u00e4tssicherung nach \u00a7 136a Absatz 5 SGB V: CAR-T-Zellen bei B-Zell-Neoplasien. 2021. Accessed 14 June 2022. ."},{"issue":"4","key":"2023061218532895500_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"21","key":"2023061218532895500_bib13","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2023061218532895500_bib14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2023061218532895500_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/10428194.2019.1691201","article-title":"Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma","volume":"61","author":"Cahill","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023061218532895500_bib16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"2023061218532895500_bib17","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2023061218532895500_bib18","doi-asserted-by":"crossref","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"2023061218532895500_bib19","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2023061218532895500_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023061218532895500_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41409-020-01014-x","article-title":"The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG","volume":"56","author":"Dalle","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023061218532895500_bib22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real world CAR consortium report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2023061218532895500_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jtct.2022.05.014","article-title":"A\u00a0bridge to CAR","volume":"28","author":"Frey","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2023061218532895500_bib24","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2023061218532895500_bib25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023061218532895500_bib26","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"26","key":"2023061218532895500_bib27","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023061218532895500_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023061218532895500_bib29","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023061218532895500_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2016.224","article-title":"Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience","volume":"52","author":"Willasch","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2023061218532895500_bib31","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3389\/fimmu.2018.01841","article-title":"Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+-selected to CD3\/CD19-depleted grafts in a retrospective multicenter study","volume":"9","author":"Salzmann-Manrique","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"2023061218532895500_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41409-022-01594-w","article-title":"Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation","volume":"57","author":"Drozdov","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023061218532895500_bib33","doi-asserted-by":"crossref","first-page":"786017","DOI":"10.3389\/fped.2021.786017","article-title":"Immune Reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions","volume":"9","author":"Yanir","year":"2021","journal-title":"Front Pediatr"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2436\/2056925\/blooda_adv-2022-008981-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2436\/2056925\/blooda_adv-2022-008981-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T18:54:02Z","timestamp":1686596042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2436\/494004\/CD19-CAR-T-cells-are-an-effective-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008981","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]}}}